{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:48:54Z","timestamp":1790434134368,"version":"4.1.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Experimental studies suggest a detrimental role for vasopressin in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). However, it is unknown whether endogenous vasopressin concentration is associated with disease severity in patients with ADPKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>\n                      Plasma copeptin concentration (a marker of endogenous vasopressin levels) was measured in 102 ADPKD patients (diagnosis based on Ravine criteria) by an immunoassay. Plasma and urinary osmolarity were also measured. To assess disease severity, GFR and effective renal blood flow were measured by continuous infusion of\n                      <jats:sup>125<\/jats:sup>\n                      I-iothalamate and\n                      <jats:sup>131<\/jats:sup>\n                      I-hippuran, total renal volume by magnetic resonance imaging, and 24-hour urinary albumin excretion by nephelometry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In these ADPKD patients, copeptin was associated with the various markers of disease severity in ADPKD (positively with total renal volume [\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      = 0.47] and albuminuria [\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      = 0.39] and negatively with GFR [\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      = \u22120.58] and effective renal blood flow [\n                      <jats:italic toggle=\"yes\">R<\/jats:italic>\n                      = \u22120.52], all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). These associations were independent of age, gender, and use of diuretics. Copeptin was furthermore associated with plasma osmolarity (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) but not with 24-hour urinary volume, 24-hour urinary osmolarity or fractional urea excretion (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.7, 0.9, and 0.3, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>On cross-sectional analysis, copeptin is associated with disease severity in ADPKD patients, supporting the results of experimental studies that suggest that vasopressin antagonists have a renoprotective effect in ADPKD and offering a good prospect for clinical studies with these agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.04560510","type":"journal-article","created":{"date-parts":[[2010,10,7]],"date-time":"2010-10-07T23:51:15Z","timestamp":1286495475000},"page":"361-368","source":"Crossref","is-referenced-by-count":87,"title":["Copeptin, a Surrogate Marker of Vasopressin, Is Associated with Disease Severity in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.2215","volume":"6","author":[{"given":"Esther","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan J.L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerjan","family":"Navis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Struck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-18-20230811","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1293-359","article-title":"Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease","volume":"5","author":"Peters","year":"1993","journal-title":"Nat Genet"},{"key":"R3-18-20230811","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease","volume":"329","author":"Gabow","year":"1993","journal-title":"N Engl J Med"},{"key":"R4-18-20230811","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"R5-18-20230811","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0008-6363(01)00328-5","article-title":"Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects","volume":"51","author":"Bankir","year":"2001","journal-title":"Cardiovasc Res"},{"key":"R6-18-20230811","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1046\/j.1523-1755.2003.00242.x","article-title":"Lillian Jean Kaplan International Prize for advancement in the understanding of polycystic kidney disease. Understanding polycystic kidney disease: A systems biology approach","volume":"64","author":"Grantham","year":"2003","journal-title":"Kidney Int"},{"key":"R7-18-20230811","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"key":"R8-18-20230811","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R9-18-20230811","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat Med"},{"key":"R10-18-20230811","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat Med"},{"key":"R11-18-20230811","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R12-18-20230811","doi-asserted-by":"crossref","first-page":"I129","DOI":"10.1161\/01.HYP.5.2_Pt_2.I129","article-title":"Plasma and platelet vasopressin in essential hypertension and congestive heart failure","volume":"5","author":"Preibisz","year":"1983","journal-title":"Hypertension"},{"key":"R13-18-20230811","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","article-title":"Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin","volume":"52","author":"Morgenthaler","year":"2006","journal-title":"Clin Chem"},{"key":"R14-18-20230811","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects","volume":"92","author":"Szinnai","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-18-20230811","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","article-title":"Copeptin: Clinical use of a new biomarker","volume":"19","author":"Morgenthaler","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"R16-18-20230811","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"R18-18-20230811","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1210\/jc.2008-1426","article-title":"Copeptin in the differential diagnosis of hyponatremia","volume":"94","author":"Fenske","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-18-20230811","first-page":"97","article-title":"A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow","volume":"20","author":"Donker","year":"1977","journal-title":"Neth J Med"},{"key":"R20-18-20230811","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1681\/ASN.V74567","article-title":"Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran","volume":"7","author":"Apperloo","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R21-18-20230811","first-page":"29","article-title":"Optimising glomerular filtration rate and effective renal plasma flow measurements using a simple pharmacokinetic model","volume":"43","author":"Zietse","year":"1995","journal-title":"Clin Nephrol"},{"key":"R22-18-20230811","doi-asserted-by":"crossref","first-page":"337","DOI":"10.5414\/CNP72337","article-title":"Glomerular filtration rate measurements by (125)I-iothalamate should be corrected for inaccurate urine collections with (131)I-hippuran","volume":"72","author":"Michels","year":"2009","journal-title":"Clin Nephrol"},{"key":"R23-18-20230811","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00004728-200007000-00019","article-title":"Volumetric measurement of renal cysts and parenchyma using MRI: Phantoms and patients with polycystic kidney disease","volume":"24","author":"Bae","year":"2000","journal-title":"J Comput Assisted Tomogr"},{"key":"R24-18-20230811","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"key":"R25-18-20230811","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-18-20230811","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"R27-18-20230811","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","article-title":"Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort","volume":"64","author":"Chapman","year":"2003","journal-title":"Kidney Int"},{"key":"R28-18-20230811","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1681\/ASN.V561349","article-title":"Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease","volume":"5","author":"Chapman","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"R29-18-20230811","first-page":"329","article-title":"[The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease]","volume":"96","author":"Michalski","year":"1996","journal-title":"Pol Arch Med Wewn"},{"key":"R30-18-20230811","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.0954-6820.1986.tb03330.x","article-title":"Expansion of extracellular volume in early polycystic kidney disease","volume":"219","author":"Danielsen","year":"1986","journal-title":"Acta Med Scand"},{"key":"R31-18-20230811","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.2009.397","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort","volume":"77","author":"Meijer","year":"2010","journal-title":"Kidney Int"},{"key":"R32-18-20230811","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients","volume":"88","author":"Meijer","year":"2009","journal-title":"Transplantation"},{"key":"R33-18-20230811","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ki.1989.38","article-title":"The clinical utility of renal concentrating capacity in polycystic kidney disease","volume":"35","author":"Gabow","year":"1989","journal-title":"Kidney Int"},{"key":"R34-18-20230811","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"R35-18-20230811","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R36-18-20230811","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0272-6386(89)80068-X","article-title":"Is gender a determinant for evolution of renal failure? A study in autosomal dominant polycystic kidney disease","volume":"14","author":"Gretz","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"R37-18-20230811","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"key":"R38-18-20230811","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1681\/ASN.V661634","article-title":"Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease","volume":"6","author":"Choukroun","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"R39-18-20230811","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1681\/ASN.V76842","article-title":"Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action","volume":"7","author":"Bouby","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"R40-18-20230811","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1248\/bpb.24.897","article-title":"Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to the evaluation of the pharmacologic profile of VP-343, a selective vasopressin V2 receptor antagonist","volume":"24","author":"Naito","year":"2001","journal-title":"Biol Pharm Bull"},{"key":"R41-18-20230811","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/ndt\/18.3.497","article-title":"Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system","volume":"18","author":"Bardoux","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"R42-18-20230811","first-page":"F973","article-title":"Effect of water intake on the progression of chronic renal failure in the 5\/6 nephrectomized rat","volume":"258","author":"Bouby","year":"1990","journal-title":"Am J Physiol"},{"key":"R43-18-20230811","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0024-3205(99)00330-6","article-title":"Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats","volume":"65","author":"Bouby","year":"1999","journal-title":"Life Sci"},{"key":"R45-18-20230811","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1042\/cs0860399","article-title":"Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats","volume":"86","author":"Okada","year":"1994","journal-title":"Clin Sci (Lond"},{"key":"R46-18-20230811","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1046\/j.1523-1755.1999.00443.x","article-title":"High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta","volume":"55","author":"Sugiura","year":"1999","journal-title":"Kidney Int"},{"key":"R47-18-20230811","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/CS20080140","article-title":"Gender and renal function influence plasma levels of copeptin in healthy individuals","volume":"116","author":"Bhandari","year":"2009","journal-title":"Clin Sci (Lond"},{"key":"R48-18-20230811","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI108377","article-title":"Distribution, blood transport, and degradation of antidiuretic hormone in man","volume":"57","author":"Baumann","year":"1976","journal-title":"J Clin Invest"},{"key":"R49-18-20230811","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1651-2227.2007.00587.x","article-title":"Renal concentrating capacity as a marker for glomerular filtration rate","volume":"97","author":"Garcia Nieto","year":"2008","journal-title":"Acta Paediatr"},{"key":"R50-18-20230811","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1056\/NEJM196905222802101","article-title":"Vasopressin-resistant hyposthenuria in advanced chronic renal disease","volume":"280","author":"Tannen","year":"1969","journal-title":"N Engl J Med"},{"key":"R51-18-20230811","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2215\/CJN.00360110","article-title":"Early renal abnormalities in autosomal dominant polycystic kidney disease","volume":"5","author":"Meijer","year":"2010","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:40:19Z","timestamp":1786369219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201102000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04560510","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}